Working… Menu

The Effect of the Nutraceutical "Hemofix" on the Coagulation System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01651468
Recruitment Status : Withdrawn (The collaborator lost interest in a clinical study.)
First Posted : July 27, 2012
Last Update Posted : November 28, 2017
Yocheved Grossman
Idan Grossman
Information provided by (Responsible Party):
Hadassah Medical Organization

Brief Summary:
Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to assist in wound healing and bleeding arrest. It contains herbs such as Red Clover, Liquorice, Raspberry, Ginger and more. The present study will evaluate the formula on the coagulation system.

Condition or disease Intervention/treatment Phase
Von Willebrand Disease Menorrhagia Dietary Supplement: HEMOFIX Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Phase 1 Study of the Nutraceutical "Hemofix" Safety and Effect on the Coagulation System
Study Start Date : September 2016
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: HEMOFIX
3 grams a day
Dietary Supplement: HEMOFIX
unique complex herbal mixture

Primary Outcome Measures :
  1. bleeding and blood test results [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers and volunteers with a mild bleeding disorder

Exclusion Criteria:

  • people with thrombophilic and cardiovascular complications,
  • people who are treated with anti-coagulants,
  • women taking birth control pills
  • people with a history hypercoagulability

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01651468

Layout table for location information
Hadassah Medical Organization
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Yocheved Grossman
Idan Grossman
Layout table for investigator information
Principal Investigator: David Varon, Prof HMO
Layout table for additonal information
Responsible Party: Hadassah Medical Organization Identifier: NCT01651468    
Other Study ID Numbers: HEMOFIX- HMO-CTIL
First Posted: July 27, 2012    Key Record Dates
Last Update Posted: November 28, 2017
Last Verified: February 2017
Keywords provided by Hadassah Medical Organization:
mild bleeding disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Von Willebrand Diseases
Uterine Hemorrhage
Uterine Diseases
Pathologic Processes
Menstruation Disturbances
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Blood Platelet Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn